Physician profile
Franc Wallace
NPI 1326026915
$1,498.52
in general payments reported to CMS, 2019-2025
29 companies · $360 in 2025
The $360 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $418 · 2020: $24.14 · 2021: $136 · 2024: $559 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $920.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $919.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $200.17 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $162.99 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Astellas Pharma US INC | $129.06 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $124.45 | 2021 | |
| Adaptive Biotechnologies Corporation | $105.14 | 2024 | Clonoseq |
| Astrazeneca Pharmaceuticals LP | $82.52 | 2019-2025 | |
| Lilly USA, LLC | $61.58 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
| Abbvie INC. | $59.64 | 2024-2025 | |
| Servier Pharmaceuticals LLC | $53.57 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $45.76 | 2019 | |
| Incyte Corporation | $40.70 | 2024 | Jakafi |
| Sun Pharmaceutical Industries INC. | $38.53 | 2024 | |
| Jazz Pharmaceuticals INC. | $38.49 | 2024-2025 | |
| Coherus Oncology, INC. | $36.73 | 2024 | |
| Beone Medicines USA, INC. | $33.73 | 2025 | Brukinsa |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $32.97 | 2019 | |
| Geron Corporation | $32.59 | 2025 | Rytelo |
| Azurity Pharmaceuticals, INC. | $30.43 | 2025 | Vivimusta |
| Amag Pharmaceuticals, INC. | $23.70 | 2019 | |
| Abbott Laboratories | $23.45 | 2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Genzyme Corporation | $21.38 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.07 | 2025 | Fruzaqla |
| Accord Healthcare, INC. | $18.57 | 2025 | |
| Beigene USA, INC. | $17.09 | 2024 | Brukinsa |
| Genmab U.S., INC. | $14.10 | 2024 | Tivdak |
| Recordati_rare_diseases_inc. | $14.07 | 2025 | Sylvant |
| Kyowa Kirin, INC. | $12.92 | 2019 | |
| Heron Therapeutics, INC. | $12.20 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Franc Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.